Can quetiapine (Seroquel) help treat akathisia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Quetiapine (Seroquel) Help Treat Akathisia?

Yes, quetiapine can help treat akathisia and is specifically recommended as a treatment option by switching to it from other antipsychotics that cause akathisia. 1

Guideline-Based Recommendations

The most recent international guidelines (2025) explicitly state that akathisia can be managed by switching to quetiapine or olanzapine 1. This represents a clear, evidence-based strategy where quetiapine serves as an akathisia-sparing antipsychotic rather than just an adjunctive treatment.

The American Psychiatric Association guidelines (2020) provide a broader framework for akathisia management, suggesting three options: lowering the antipsychotic dose, switching to another antipsychotic, adding a benzodiazepine, or adding a beta-blocker 2. However, the 2025 guidelines are more specific in identifying quetiapine as a preferred switch option.

Clinical Evidence Supporting Quetiapine's Role

Quetiapine has one of the lowest akathisia rates among all antipsychotics:

  • In first-episode psychosis patients, quetiapine had only a 3.5% incidence of akathisia compared to haloperidol (57%), risperidone (20%), aripiprazole (18.2%), and ziprasidone (17.2%) 3
  • Only olanzapine (3.6%) had a comparable low rate 3
  • A dose-response meta-analysis found that quetiapine carried negligible risk for akathisia across all examined doses with a flat dose-response curve 4
  • In bipolar mania trials, quetiapine's akathisia incidence (3.3%) was similar to placebo (6.1%) 5

FDA Label Information

The FDA label for Seroquel confirms low akathisia rates in clinical trials:

  • In bipolar depression studies, akathisia occurred in 4% of quetiapine patients vs. 1% on placebo 6
  • In adolescent schizophrenia trials, akathisia rates were 4.8% for quetiapine vs. 4.0% for placebo 6

Practical Treatment Algorithm

When a patient develops akathisia on another antipsychotic:

  1. First-line approach: Switch to quetiapine (or olanzapine) as these are the only true akathisia-sparing second-generation antipsychotics 1, 3

  2. Alternative approaches if switching is not feasible:

    • Reduce the dose of the current antipsychotic 1, 2
    • Add propranolol 10-30 mg two to three times daily 1
    • Add a benzodiazepine 2
  3. Dosing considerations: Quetiapine's akathisia-sparing effect appears consistent across the dose range, as the dose-response curve remains flat 4

Important Caveats

  • Quetiapine is not typically used as an adjunctive treatment for akathisia caused by other antipsychotics—it works by being the primary antipsychotic instead
  • The mechanism likely relates to quetiapine's lower D2 receptor affinity and broader receptor profile compared to higher-potency antipsychotics
  • While one case report suggested quetiapine as part of combination therapy for cathinone-induced akathisia, this was ineffective 7, highlighting that quetiapine works best when it replaces the offending agent rather than being added to it
  • Treatment-resistant akathisia may require combination approaches including beta-blockers, benzodiazepines, or emerging evidence for mirtazapine 8, 9

Quality of Life Impact

Akathisia is severely distressing and can lead to medication non-adherence, worsening psychosis, and even suicidality. Switching to quetiapine addresses both the underlying psychiatric condition and eliminates the akathisia, making it a superior strategy compared to adding multiple medications to manage side effects while continuing the offending antipsychotic.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.